Last reviewed · How we verify
low dose ruxolitinib
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses.
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses. Used for Myelofibrosis, Polycythemia vera.
At a glance
| Generic name | low dose ruxolitinib |
|---|---|
| Sponsor | Beijing Friendship Hospital |
| Drug class | JAK inhibitor |
| Target | JAK1 and JAK2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting JAK1 and JAK2, ruxolitinib reduces the production of pro-inflammatory cytokines and mediators, leading to anti-inflammatory effects. This mechanism is particularly beneficial in treating conditions characterized by excessive immune activation, such as myeloproliferative neoplasms.
Approved indications
- Myelofibrosis
- Polycythemia vera
Common side effects
- Anemia
- Thrombocytopenia
- Neutropenia
Key clinical trials
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts (PHASE4)
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (PHASE1, PHASE2)
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PHASE3)
- Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma (PHASE2)
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (PHASE2)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease (PHASE1, PHASE2)
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose ruxolitinib CI brief — competitive landscape report
- low dose ruxolitinib updates RSS · CI watch RSS
- Beijing Friendship Hospital portfolio CI